| BASILEA N |
| 日付/時刻 | / |
| 変化 / 変化(%) | - / |
| Bid | - |
| Ask | - |
| 始値 | - |
| 直前終値 | - |
| 高値 | - |
| 安値 | - |
| 出来高 [CHF] | - |
| 出来高 [Units] | |
| Price fixings | |
| ISIN | CH0011432447 |
| シンボル | BSLN |
| 取引所 | SIX Swiss Exchange |
| 種類 | 株式 |
すべての取引所
| 取引所 | 直近 | 出来高 | |
|---|---|---|---|
| SIX Swiss Ex.. | 31,000 |  |
27.436 |
| London Domes.. | 31,08 | |
1.546 |
| Cboe Europe .. | 30,90 |  |
1.229 |
| Cboe Europe .. | 31,25 | |
499 |
| Turquoise | 31,05 | |
350 |
| Lang & Schwa.. | 29,50 | |
|
| Nasdaq Other.. | 41,0000 | 40 | |
| München | 32,300 | 0 | |
| Berlin | 32,100 | 0 | |
| Frankfurt | 32,2800 | 0 | |
| gettex | 32,340 | ||
| TradeGate | 30,300 | 33 | |
| EUREX | Options | ||
ニュース
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire